×
Back to Agenda
Session 5: What Will Biosimilars Look Like in Five Years?
Session Chair(s)
Anna Welch, MA
Chief Editor, Biosimilar Development, Life Science Connect, United States
As biosimilar stakeholders evaluate the appropriate metrics of success for the current wave of products, it’s important to consider how the industry’s market dynamics may shift in the future. Looking ahead, there are several critical questions to consider, including:
- Which company models will be best suited for the future market, and why?
- What types of products will be chosen as future biosimilar development candidates?
- What development challenges will these products pose for companies?
- How will companies strive to differentiate their biosimilar products or development process?
Learning Objective : At the conclusion of this session, participants should be able to:
- Evaluate the next wave of the biosimilar pipeline and the opportunities/challenges it will pose for the industry
- Understand best business practices (i.e., product selection and differentiation strategies) that can be employed to remain in the biosimilar market long-term
- Evaluate novel manufacturing and outsourcing strategies to reduce COGs
Speaker(s)
Murray Aitken, MBA
Executive Director, IQVIA Institute for Human Data Science, United States
Speaker
Michiel Ultee, PHD, MS
Principal, Ulteemit Bioconsulting, United States
Speaker
Alexandra Moulson, MBA, MS
VP Strategy, Programs and Portfolio, Polpharma Biologics, Poland
Speaker
George I'ons
Head of Product Strategy & Insights, Owen Mumford, Ltd, United Kingdom
Speaker
Have an account?